The narrow field of cell therapies — currently focused on blood cancers — could soon be used to treat far more common tumors, autoimmune diseases, or even viruses, biotech executives told a crowd in Boston Thursday.
“People landed on the moon, right?” said Usman Azam, president and CEO of Tmunity, likening that achievement to two landmark FDA approvals for CAR-T drugs: Novartis’s leukemia drug Kymirah, and Gilead-owned Kite’s Yescarta, which is used to treat a form of non-Hodgkin lymphoma. “We now want to jump to Jupiter.”
About the Author Reprints
